Dr. Richon is a scientifically trained executive with decades of leadership experience in small biotechnology companies, global pharmaceutical companies and academia. Before joining Ribon, Dr. Richon was the Vice President and Global Head of Oncology Research and Translational Medicine at Sanofi where she led the company’s early oncology efforts. Prior to Sanofi, Dr. Richon was Vice President of Biological Sciences at Epizyme, Inc., a biotechnology company pioneering therapeutics based upon epigenetics. Earlier in her career, she was Founder and Executive Director of Aton Pharmaceuticals which was acquired by Merck in 2004. Aton was formed to develop HDAC inhibitors, including vorinostat, an HDAC inhibitor that Dr. Richon developed during her tenure at Sloan-Kettering Cancer Center and vorinostat was the first HDAC inhibitor approved by the FDA while she was at Merck.
Dr. Richon received her PhD in Biochemistry at the University of Nebraska Medical Center and a BA in Chemistry at the University of Vermont.
Dr. Chang is an expert in the biology of PARPs and a leader in the field. Prior to joining Ribon, Dr. Chang was the Howard S. and Linda B. Stern Assistant Professor at the Koch Institute for Integrative Cancer Research at MIT where his laboratory focused on PARPs and their role in cancer stress response. While at MIT, Dr. Chang received many awards including the Rita Allen Foundation fellow and Sidney Kimmel Foundation for Cancer Research fellow. He has authored numerous publications and presentations. Dr. Chang was the organizer and Co-chair (2015) and is the Chair (2017) of the NAD+ Signaling and Metabolism conference sponsored by the Federation of American Societies for Experimental Biology.
Dr. Chang received his PhD in Biology at Stanford University and completed a postdoctoral fellowship at Harvard Medical School with Tim Mitchison. He completed his BS at the University of Wisconsin-Madison.
Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 12 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies. Prior to joining Ribon, Dr. Keilhack was Senior Director of Biology at Epizyme where, among other responsibilities, she was the project leader for the company’s EZH2 inhibitor program, currently in Phase 2 clinical testing. Before that, she was a research fellow at Merck and the biology project lead for the company’s clinical stage AKT inhibitor, MK-2206.
Dr. Keilhack received her PhD in Biochemistry at Friedrich Schiller University of Jena (Germany) and completed postdoctoral training at the Harvard Medical School. She earned a BS in Biochemistry at Martin Luther University of Halle-Wittenberg (Germany).
Dr. Kuntz is an experienced and successful drug discovery scientist with over 15 years of experience, including extensive research in kinase inhibitors and protein methyltransferase inhibitors. Prior to joining Ribon, he was Head of Chemistry at Epizyme. While at Epizyme, Dr. Kuntz invented tazemetostat, a small molecule currently in multiple phase 2 trials to treat lymphomas and solid tumors. Earlier in his career, he was a researcher at GlaxoSmithKline and Avila Therapeutics. While at GSK, Dr. Kuntz was a co-inventor of dabrafenib, a BRAF inhibitor approved to treat melanoma.
Dr. Kuntz received his PhD in Organic Chemistry at Boston College and BS in Chemistry at Trinity University.
David Cordo has been working in the life sciences industry since 1990. He held senior management positions in finance at Biogen Idec and during his seven-year tenure was involved in the worldwide commercial launch of Avonex, the company’s first billion dollar drug. For seven years, David was the Treasurer of Millennium Pharmaceuticals until May 2006. At Millennium, he led finance teams in the raising of an $800M follow-on equity offering and a $400M convertible debt offering. Since leaving Millennium, David has been Interim Chief Financial Officer for Epizyme, Dicerna Pharmaceuticals, CoStim Pharmaceuticals, Mitobridge, Potenza Therapeutics, Preceres, Metamark Genetics and Avila Therapeutics.
David is a CPA and received his MBA from Nichols College and his BSBA from Stonehill College.